Nominal and neighboring-optimal control approaches to the adoptive immunotherapy for cancer

Chelur DS, Chalfie M (2007) Targeted cell killing by reconstituted caspases. Proc Natl Acad Sci 104(7):2283–2288

Martin RB (1992) Optimal control drug scheduling of cancer chemotherapy. Automatica 28(6):1113–1123

Swan GW (1990) Role of optimal control theory in cancer chemotherapy. Math Biosci 101(2):237–284

Engelhart M, Lebiedz D, Sager S (2011) Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function. Math Biosci 229(1):123–134

Zouhri S, Saadi S, Elmouki I, Hamdache A, Rachik M (2013) Mixed immunotherapy and chemotherapy of tumors: optimal control approach. Int J Comput Sci Issues 10(4):1

Bomford CK, Kunkler IH (1993) Walter and Miller’s textbook of radiotherapy: radiation physics, therapy, and oncology. Churchill Livingstone, London

Castiglione F, Piccoli B (2007) Cancer immunotherapy, mathematical modeling and optimal control. J Theor Biol 247(4):723–732

De Pillis LG, Gu W, Radunskaya AE (2006) Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J Theor Biol 238(4):841–862

Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumorimmune interaction. J Math Biol 37(3):235–252

Chan C, George AJ, Stark J (2003) T cell sensitivity and specificity-kinetic proofreading revisited. Discrete Contin Dyn Syst Ser B 3(3):343–360

Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305(5681):200–205

Starkov KE, Krishchenko AP (2014) On the global dynamics of one cancer tumour growth model. Commun Nonlinear Sci Numer Simul 19(5):1486–1495

Beerenwinkel N, Schwarz RF, Gerstung M, Markowetz F (2015) Cancer evolution: mathematical models and computational inference. Syst Biol 64(1):e1–e25

Babaei N, Salamci MU (2014) State dependent riccati equation based model reference adaptive stabilization of nonlinear systems with application to cancer treatment. In: Proceedings of the 19th IFAC World Congress, Cape Town, South Africa

Babaei N, Salamci MU (2015) Personalized drug administration for cancer treatment using model reference adaptive control. J Theor Biol 371:24–44

Swanson KR, Bridge C, Murray JD, Alvord EC (2003) Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 216(1):1–10

Bunimovich-Mendrazitsky S, Shochat E, Stone L (2007) Mathematical model of BCG immunotherapy in superficial bladder cancer. Bull Math Biol 69(6):1847–1870

Elmouki I, Saadi S (2014) BCG immunotherapy optimization on an isoperimetric optimal control problem for the treatment of superficial bladder cancer. Int J Dyn Control 1–7. doi: 10.1007/s40435-014-0106-5

Saadi S, Elmouki I, Hamdache A (2015) Impulsive control dosing BCG immunotherapy for non-muscle invasive bladder cancer. Int J Dyn Control 3(3):313–323

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16):3670–3679

Nazari M, Ghaffari A (2015) The effect of finite duration inputs on the dynamics of a system: proposing a new approach for cancer treatment. Int J Biomath 8(03):1550036

Nazari M, Ghaffari A, Arab F (2015) Finite duration treatment of cancer by using vaccine therapy and optimal chemotherapy: state-dependent Riccati equation control and extended Kalman filter. J Biol Syst 23(01):1–29

Ghaffari A, Nazari M, Arab F (2015) Suboptimal mixed vaccine and chemotherapy in finite duration cancer treatment: state-dependent Riccati equation control. J Braz Soc Mech Sci Eng 37(1):45–56

Sahami F, Salamci MU (2015) Decentralized model reference adaptive control design for nonlinear systems; state dependent Riccati equation approach. In: 2015 16th international Carpathian control conference (ICCC), IEEE, pp 437–442

Cimen T (2008) State-dependent Riccati equation (SDRE) control: a survey. In: Proceedings of the 17th World Congress of the international federation of automatic control (IFAC). Seoul, Korea, July, pp 6–11

Naidu DS (2002) Optimal control systems, vol 2. CRC Press, Boca Raton

Dutcher J (2002) Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) 16(11 Suppl 13):4–10

Hamdache A, Saadi S, Elmouki I, Zouhri S (2013) Two therapeutic approaches for the treatment of HIV infection in AIDS stage. Appl Math Sci 7(105):5243–5257

Rosenberg SA (2008) Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci 105(35):12643–12644

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915

Zitvogel L, Kroemer G (2008) Introduction: the immune response against dying cells. Curr Opin Immunol 20(5):501–503

Hamdache A, Elmouki I, Saadi S (2014) Optimal control with an isoperimetric constraint applied to cancer immunotherapy. Int J Comput Appl 94(15):31–37

Burden TN, Ernstberger J, Fister KR (2004) Optimal control applied to immunotherapy. Discrete Contin Dyn Syst Ser B 4(1):135–146

Ben-Ami E, Schachter J (2015) Adoptive transfer of tumor-infiltrating lymphocytes for melanoma: new players, old game. Immunotherapy 7(5):477–479

Stengel RF, Ghigliazza RM, Kulkarni NV (2002) Optimal enhancement of immune response. Bioinformatics 18(9):1227–1235

Fleming W, Rishel R (1975) Deterministic and stochastic optimal control. Springer, New York

Pontryagin LS (1987) Mathematical theory of optimal processes. CRC Press, Boca Raton

Stengel RF (2012) Optimal control and estimation. Courier Corporation, North Chelmsford

Lenhart S, Workman JT (2007) Optimal control applied to biological models. CRC Press, Boca Raton

McAsey M, Mou L, Han W (2012) Convergence of the forward-backward sweep method in optimal control. Comput Optim Appl 53(1):207–226

Graves RN (2010) A method to accomplish the optimal control of continuous dynamical systems with impulse controls via discrete optimal control and utilizing optimal control theory to explore the emergence of synchrony

Brugnano L, Iavernaro F, Trigiante D (2015) Analysis of Hamiltonian boundary value methods (HBVMs): a class of energy-preserving Runge–Kutta methods for the numerical solution of polynomial Hamiltonian systems. Commun Nonlinear Sci Numer Simul 20(3):650–667

Kirschner D, Tsygvintsev A (2009) On the global dynamics of a model for tumor immunotherapy. Math Biosci Eng 6(3):573–583

Starkov KE, Coria LN (2013) Global dynamics of the Kirschner–Panetta model for the tumor immunotherapy. Nonlinear Anal Real World Appl 14(3):1425–1433

Banerjee S (2008) Immunotherapy with interleukin-2: a study based on mathematical modeling. Int J Appl Math Comput Sci 18(3):389–398

Lukes DL (1982) Differential equations. Elsevier, Amsterdam

Elmouki I, Saadi S (2015) Quadratic and linear controls developing an optimal treatment for the use of BCG immunotherapy in superficial bladder cancer. Optim Control Appl Methods . doi: 10.1002/oca.2161

Trelat E (2005) Contrôle optimal: théorie et applications. Vuibert, Paris

Meyer GH (1973) Initial value methods for boundary value problems. Academic Press, New York

Ramirez WF (1994) Process control and identification. Academic Press, New York

Cheney E, Kincaid D (2012) Numerical mathematics and computing. Cengage Learning, Boston

Zill D, Wright W (2012) Differential equations with boundary-value problems. Cengage Learning, Boston

Grewal MS, Andrews AP (2011) Kalman filtering: theory and practice using MATLAB. Wiley, New York

Xue D, Chen Y (2008) Solving applied mathematical problems with MATLAB. CRC Press, Boca Raton

Siddiqui I, Mantovani A, Allavena P (2015) Adoptive T-cell therapy: optimizing chemokine receptor-mediated homing of T cells in cancer immunotherapy. In: Rezaei N (ed) Cancer immunology. Bench to bedside immunotherapy of cancers. Springer, Berlin, pp 263–282

Darcy PK, Neeson PJ (2015) Adoptive immunotherapy: a new era for the treatment of cancer. Immunotherapy 7(5):469–471

Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230):62–68

Stefanovic S, Schuetz F, Sohn C, Beckhove P, Domschke C (2014) Adoptive immunotherapy of metastatic breast cancer: present and future. Cancer Metastasis Rev 33(1):309–320

Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Oka M (2014) Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med 12:175

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–2357

Shaffer DR, Cruz CRY, Rooney CM (2013) Adoptive T cell transfer. In: Curiel TJ (ed) Cancer immunotherapy. Paradigms, practice and promise. Springer, New York, pp 47–70